420 with CNW — Senators Say DEA Rule on THC Content of Hemp Contravenes Congressional Intent

October 29, 2020 15:24:16

In August, the Drug Enforcement Administration (“DEA”) unveiled proposed rules that would officially put the agency in line with the 2018 farm bill. The legislation legalized the cultivation and sale of industrial hemp and its extracts, allowing farmers across the country to grow hemp under state and tribal programs. However, the federal agency’s interim final rule on hemp has been met with resistance from activists who argue it contradicts the 2018 farm bill and will hamper the growth of the nascent hemp industry.

Last week, a pair of Oregon senators sent a letter to the DEA demanding changes to its proposed hemp regulations. Senators Ron Wyden and Jeff Merkley say that despite the DEA’s claim…

Read More >>

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Talks Porcine Usage, Producing Synthetic Alternative

October 29, 2020 15:01:46

AzurRx BioPharma (NASDAQ: AZRX), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, recently talked about its usage of porcine (pig) products in its production of pharmaceuticals and medicinals. Included in the discussion was a look at the disadvantages of such usage. AzurRx noted that pigs have been used for centuries in medical research and development; in fact, one study noted that pigs had been used in an estimated 20 medications and pharmaceuticals  including six for the pancreas, which are of particular interest for AZRX. There are downsides to such usage, the company noted, including supply chain, concentration and purity issues. Because of these issues, AzurRx is hoping  to develop synthetic replacement products. One of AZRX’s most promising treatments is MS1819, a lead product candidate being studied for the treatment of exocrine pancreatic insufficiency (“EPI”) associated with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). The company is currently involved in several clinical trials for the drug, including two trial sites that were recently activated in Turkey. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” AzurRx chief medical officer Dr. James Pennington stated in the press release. “The recently reported interim data suggests promising results, and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the startup of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”

To view the full press release, visit https://ibn.fm/dZk2B

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, NY, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

CBDNewsBreaks – The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) Announces Addition of BettermentRS, a Leading CBD Distributor

October 29, 2020 14:42:41

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER), a producer of premium bottled alkaline water, flavor-infused waters and CBD-infused products, has added health and wellness, CBD-focused, direct-store delivery (DSD) distributor BettermentRS to its list of distributors. The move will enhance WTER’s convenience and grocery store CBD-sales growth. Based on recent research, sales of hemp-derived CBD products in the United States totaled $4.2 billion in 2019, which represents a 562% increase over the previous year. During the same period, sales of CBD products at c-stores and gas stores grew by more than 2,275%, topping out $122 million. The research also noted that CBD-infused drinks, tinctures and topicals are growth opportunities in the channel. In addition, the research reported that CBD drinks were valued at $52 million in c-store sales in 2019 and that CBD drinks are projected to remain popular among new consumers. “We are thrilled to partner with BettermentRS to represent A88CBD brand to some of the nation’s largest and fast-growing retail chains,” said The Alkaline Water Company president and CEO Ricky Wright in the press release. “BettermentRS will provide sales management, marketing, and logistics expertise to accelerate sales for our A88CBD line of products, particularly in the convenience store channel. CBD sales in the c-store channel are booming and represent a tremendous opportunity for our in-demand lifestyle brands. Sales of hemp-derived CBD products in the c-store channel were approximately $122 million in 2019 and grew roughly four times faster than the overall CDB market. BettermentRS will work closely with our sales team to introduce our brands to large accounts, including aforementioned, 7-Eleven and YesWay. . . .As a trusted national brand, we now offer a robust line of high-quality, lab-tested CBD topical and ingestible products. Our recent product announcements include gummies and CBD infused lemon-lime flavored water for our ingestibles line and deep relief cream and bath bombs for our topical line. With additional exciting new products and flavors coming soon and a growing base of strong channel partners, our A88CBD brand is well-positioned to capitalize on the increasing demand for CBD products across various trade channels.”

To view the full press release, visit https://cnw.fm/0hMh4

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

Study Suggests Psychedelics May Encourage Connectedness, Reduce Narcissism

October 29, 2020 14:37:21

In a new study published in “Psychopharmacology,”, researchers argue that feelings of awe elicited from psychedelic drugs may influence narcissistic personality traits positively. The study discovered that psychedelic experiences that evoke feelings of awe were connected to increased feelings of empathy and connectedness, which are linked to reduced levels of exploitative-entitled narcissism.

Because prior research had demonstrated that psychedelic substances could improve mental well-being and intensify feelings of social connectedness, the researchers of this study chose to instead focus on finding out whether the effects from these substances…

Read More >>

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

InvestorNewsBreaks – Taat Lifestyle & Wellness Ltd (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) Prepares for Ohio Launch

October 29, 2020 13:55:54

Taat Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) recently announced that its contract manufacturing partner has begun the inaugural commercial-scale production batch of Taat after receiving its supply of Beyond Tobacco(TM) base material. This batch will be packaged using an updated Taat design, substantially similar to the provisional pack designs published in the company’s September 29, 2020, press release. Taat expects initial production to be completed in November 2020, after which inventory will be shipped from the manufacturer’s warehouse to tobacco wholesalers in Ohio. These wholesalers will then be able to fulfill orders for Taat from tobacco retailer accounts in the convenience channel.

To view the full press release, visit https://ibn.fm/6L3ai

About Taat Lifestyle & Wellness Ltd.

Having developed Beyond Tobacco(TM), which contains no tobacco or nicotine, Taat’s objective is to introduce an innovative, experience-driven alternative to tobacco cigarettes for tobacco smokers who aspire to leave nicotine behind. Beyond Tobacco(TM), which is to be offered in “Original” and “Menthol” varieties, is designed to closely emulate every aspect of smoking a traditional cigarette. From the cigarette-style packaging and stick format, to the proprietary flavoring blend which imparts the flavor and scent of tobacco, to the draw sensation, and the amount of smoke exhaled, Beyond Tobacco(TM) has been meticulously engineered to enable smokers to continue enjoying the experience of smoking, while discontinuing nicotine intake. Taat plans to launch Beyond Tobacco(TM) in mid-Q4 2020 and is seeking to position itself in the USD $814 billion (2018) 1 global tobacco industry to capitalize on the growing worldwide demand for alternatives to traditional cigarettes. For more information, please visit www.TaatUSA.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

ev Transportation Services Inc. Is ‘One to Watch’

October 29, 2020 13:41:30
  • evTS provides a versatile, purpose built, all-electric light duty utility vehicle, the Firefly ESV, that can be customized for various service industry applications
  • Its durable modular design, agility and long-lasting battery make it an ideal vehicle for a wide range of tasks and operations in sectors such as parking enforcement, security, building maintenance, last-mile urban delivery and more
  • The 2021 FireFly ESV model has been updated with enhanced features, including the proprietary evTS Connected Vehicle System
  • ADOMANI Inc., a provider of zero-emission electric vehicles, signed a letter of intent earlier in 2020 to purchase and distribute the FireFly ESV
  • The management team for evTS is comprised of individuals who have extensive experience in the electric vehicle, automotive distribution, software and engineering industries
  • The global electric vehicle market is projected to reach $820.81 billion by 2027, up from a recorded $162.34 billion in 2019

ev Transportation Services (“evTS”) is a designer, developer and manufacturer of all-electric lightweight commercial vehicles and fleet management solutions.

Founded in 2015 in Brookline, Massachusetts, and currently based in Boston, the company is focused on the essential transportation services market. End-user applications for evTS vehicles include…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to ev Transportation Services are available in the company’s newsroom at https://ibn.fm/EVTS

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

The Benefits, Drawbacks of Buying Used Electric Vehicles

October 29, 2020 13:34:16

With the electric vehicle (“EV”) industry growing older, customers who would like to reduce their carbon footprints now have the option of buying a used electric vehicle. Because these vehicles cost less to run and maintain, they tend to have more value for money than conventional used cars. But before you make any purchases, check out these pros and cons to help you decide whether a used EV is the best choice for you.

Let’s start…

Read More >>

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Cannabis Global Inc.’s (CBGL) Advanced CBD Infusion Technologies Featured in SmallCapVoice.com Interview

October 29, 2020 13:19:14

Cannabis Global (OTC: CBGL), a science-forward company developing CBD infusion technologies and products while investing in fast-growing segments of the cannabis industry, was featured in a new interview with SmallCapVoice.com, Inc. (“SCV”). Among other topics, CBGL CEO Arman Tabatabaei joined SCV’s Stuart Smith to discuss Cannabis Global’s HempYouCanFee(TM) product line, as well as a new partnership that provides international reach. Tabatabaei discusses several provisional patents Cannabis Global has on deck, three of which are at the forefront of its growth strategy. Describing Cannabis Global’s CBD coffee pods and other exciting innovative products, as well as its ability to create new forms of polymeric cannabinoid nanoparticles, Tabatabaei says the company’s technologies wield great potential for the cannabis market. “We’ve filed six provisional patents . . . and the upcoming non-provisional patent on the nanotechnology, we think, could re-write the cost model for a large segment of the [cannabis] industry,” Tabatabaei says in the interview.

To view the full press release, visit https://cnw.fm/liX4R

About Cannabis Global Inc.

Cannabis Global, formerly known as MCTC Holdings Inc., is a fully audited and reporting company with the U.S. Securities & Exchange Commission, trading with the stock symbol CBGL. The company is an emerging force in cannabinoid sciences and highly bioavailable hemp and cannabis infusion technologies. Cannabis Global has an actively growing portfolio of cannabis investments and intellectual property, having filed six provisional patents relative to the areas of cannabinoid delivery systems and cannabinoid polymeric nanoparticles. The company markets its consumer products under the Hemp You Can Feel(TM) brand name. Cannabis Global launched its Project Varin early in 2020 to develop new delivery methods for rare cannabinoid tetrahydrocannabivarin (“THV-C”) and develop products based on this cannabinoid. For more information, visit the company’s website at www.CannabisGlobalInc.com.

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://cnw.fm/MCTC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Five Companies That Could Win Tesla’s Giant Nickel Contract

October 29, 2020 13:05:10

Earlier in July this year, Tesla’s Elon Musk asked miners to mine more nickel. He pledged a “giant contract” for any firm that could mine nickel in an environmentally and economically sensitive way. Many speculate this to be an indication of Tesla upscaling its production of lithium-ion batteries. Forecasts show that Tesla may reach production of 5 million electric vehicles (EVs) by 2025.

So assuming each Tesla EV requires roughly 55 kilograms of nickel, and Tesla manufactures 5 million electric vehicles annually, the company…

Read More >>

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Secures $11.5M in Upsized Public Offering

October 29, 2020 13:02:03

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a Vancouver, Canada-based company focused on manufacturing pharmaceutical-grade cannabinoids via synthetic biology, has closed its previously announced upsized public offering of 17,692,307 units of the company, each at a price of $0.65, including 2,307,692 units issued pursuant to the full exercise of the over-allotment option. The company secured aggregate gross proceeds of approximately $11.5 million in the offering. Williow Biosciences expects to use net proceeds for the commercialization of cannabigerol (“CBG”) and other portfolio cannabinoids of the company, general and administrative expenses, working capital and general corporate purposes.

To view the full press release, visit https://cnw.fm/H026W

About Willow Biosciences Inc.

Willow is a Canadian biotechnology company based in Vancouver, Canada, that produces high purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders and other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life changing drugs. For more information, visit the company’s website at www.WillowBio.com.

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://cnw.fm/WLLW

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

InvestorNewsBreaks – Organic Flower Investments Group Inc. (CSE: SOW) (OTC: QILFF) (FWB: 2K6) Looks to Augment Portfolio with Hydrogen Sector Investment

October 29, 2020 12:45:14

Organic Flower  (CSE: SOW) (OTC: QILFF) (FWB: 2K6) recently announced its entry into a letter of intent to acquire up to a 13% equity interest in a U.S.-based company, which owns certain hydrogen assets with global applications. According to the update, the purchase price is CA$4,500,000 payable in cash. Under the terms of the arms-length acquisition, Organic Flower also has an option to increase its ownership to 90% of the assets, primarily consisting of small footprint, environmentally friendly IP for the modularized and lowest-tier production cost of hydrogen. Having successfully distributed its interest in AgraFlora Organics International Inc. to its shareholders, Organic Flower continues to be opportunistic in evaluating opportunities across all sectors, as an investor and operator, minority shareholder or sole shareholder. The company has renewed its previously disclosed investment policy (available for review on the company’ s website) to include the renewable energy sector as a potential continuing area of focus. Organic Flower now has nine investments in a variety of sectors having successfully held CA$120 million in investments during the past fiscal year and returned capital to its holders through the distribution of its AgraFlora interest.

To view the full press release, visit https://ibn.fm/JESSu

About Organic Flower Investments Group Inc.

Organic Flower is an investment company that specializes in investing into private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, the investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in our investments. For more information, visit www.SOWInvestments.ca.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

InvestorNewsBreaks – Kaival Brands Innovations Group Inc. (KAVL) Notes Upcoming Launch of Bidi Vapor’s Newest Smokeless Nicotine Product

October 29, 2020 12:36:47

Kaival Brands (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has announced the upcoming launch of the Bidi(TM) Nicotine Pouch. Kaival Brands has an exclusive partnership and distribution agreement with Bidi(TM) Vapor, the creator of the Bidi Pouch, which is designed to provide a premium smokeless nicotine experience. The pouch features a tobacco-free nicotine formulation packed into an easy-to-carry pouch. With the nicotine-pouch sector forecast to reach $3.35 billion by 2025, the potential for the new product looks to be significant. The Bidi Pouch is positioned to leverage the growing use and popularity of Bidi’s premium vape pen, the Bidi(TM) Stick, and will be distributed through existing channels. Those channels will increase as BidiVapor continues to expand its partnerships with nationally recognized convenience retail chains such as Circle K and Fas Mart. The company anticipates a rollout in more than 10,000 more partner locations this quarter. “We are excited to introduce the BidiPouch to adult consumers,” said Kaival Brands CEO Niraj Patel in the press release. “This is one of several initial steps we are taking toward our goal of providing improved products that are more sustainable. The BidiPouch does not contain any tobacco-derived substance, and we look forward to seeing its performance in the market.”

To view the full press release, visit https://ibn.fm/oaHkt

About Kaival Brands Innovations Group Inc.

Kaival Brands is focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Kaival’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate

October 29, 2020 12:19:52

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new name marks a critical branding milestone  for the company. Genprex’s REQORSA (pronounced “re-KORE-suh”) immunogene therapy features the company’s exclusive ONCOPREX(TM) nanoparticle delivery system that delivers cancer-fighting genes. The name will be resubmitted to the FDA for final review and approval after all required clinical trials are completed; that final approval is based on the FDA’s approval of the product candidate. The new name was based on FDA’s guidelines for the submission and evaluation of proprietary names. Genprex selected the name based on a comprehensive review of name candidates, including a study of healthcare practitioners across the country to guarantee accurate prescription and safety interpretation of the name. “We are very pleased to receive FDA’s conditional acceptance of our proprietary name, REQORSA, which is a necessary step toward being able to market our lead drug candidate for non-small cell lung cancer,” said Genprex president and CEO Rodney Varner in the press release. “This name approval also marks an important milestone in our overall branding strategy, giving us a unique, easily understood name people can associate with the Genprex brand and mission.”

To view the full press release, visit https://ibn.fm/H3ph0

About Genprex Inc. 

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

InvestorNewsBreaks – Creatd Inc. (NASDAQ: CRTD) Announces Board Appointment of Seasoned Securities Attorney

October 29, 2020 11:57:02

Creatd (NASDAQ: CRTD, CRTDW), the parent company of Vocal, a robust, proprietary technology platform for digital creators, today announced the appointment of LaBrena Jones Martin to its Board of Directors, where she will chair its Corporate Governance and Nomination Committee and serve on the Compensation and Audit Committees. Martin brings extensive legal experience at the senior management level, spanning nearly 40 years and encompassing all facets of corporate and securities law. “Over the years, it has been my privilege to work closely with LaBrena at Lehman and again at RBC, where we collaborated on many strategic, complex and mission-critical projects. She is not only a talented legal mind, but also has sharp business and management acumen,” Creatd’s Chairman of the Board, Mark Standish, said in the press release. “Creatd is well past the proof of concept and initial commercialization stages and, as a newly listed Nasdaq company, is now entering an anticipated growth momentum period. LaBrena has been a guiding force for several companies at this growth stage, and I believe she will be similarly instrumental in providing sound oversight to Creatd.”

To view the full press release, visit https://ibn.fm/iw0aJ

About Creatd Inc.

Creatd is the parent company and creator of Vocal, a robust and proprietary technology platform that uniquely serves creators, brands and audiences by providing long-form storytelling tools, advanced social features and monetization opportunities. Since launching in December 2016, Vocal has become home to approximately 750,000 content creators and over 4,000 paid subscribers of its recently launched Vocal+ membership program, attracting over 10 million monthly visitors across its network of 34 wholly owned and operated niche communities. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

PsychedelicNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Addresses Continuous Disclosure Review

October 29, 2020 11:44:16

Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) has provided an update on its efforts to resolve a continuous disclosure review that was issued earlier this year. Champignon is working closely with the British Columbia Securities Commission (“BCSC”) to coordinate the revocation of the cease trade order and hopes to provide information about a revocation of the order as soon as possible. In the update, the company noted that it has submitted all documentation requested by the BCSC in connection with the review of financial statements of AltMed Capital Corp. (“AltMed”) for the period ended June 30, 2020. The purpose of the review is to ensure compliance with the continuous disclosure obligations outlined by Canadian securities laws. Champignon was notified of the continuous disclosure review on June 19, 2020; the same day, the BCSC issued a cease trade order suspending trading in the securities of SHRM. The trade order requested reports in connection with SHRM’s acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. The requested reports were filed with the BCSC on July 21, 2020, and Champignon has continued to work with the commission to provide documentation and address additional issues that have arisen during the disclosure review process to ensure that the revocation of all orders is issued as soon as possible.

To view the full press release, visit https://ibn.fm/OOPEj

About Champignon Brands Inc.

Champignon Brands is focused on the formulation and manufacturing of novel ketamine, anesthetics and adaptogenic delivery platforms for the nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury (“mTBI”) with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.ChampignonBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.